Viking Therapeutics Inc (VKTX)
49.58
-3.99
(-7.45%)
USD |
NASDAQ |
Nov 15, 16:00
49.60
+0.02
(+0.04%)
After-Hours: 20:00
Viking Therapeutics Research and Development Expense (TTM): 91.16M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 91.16M |
| June 30, 2024 | 86.75M |
| March 31, 2024 | 76.90M |
| December 31, 2023 | 63.81M |
| September 30, 2023 | 59.48M |
| June 30, 2023 | 53.06M |
| March 31, 2023 | 52.69M |
| December 31, 2022 | 54.23M |
| September 30, 2022 | 47.90M |
| June 30, 2022 | 46.74M |
| March 31, 2022 | 46.00M |
| December 31, 2021 | 44.98M |
| September 30, 2021 | 44.18M |
| June 30, 2021 | 40.50M |
| March 31, 2021 | 35.48M |
| December 31, 2020 | 31.93M |
| September 30, 2020 | 29.33M |
| June 30, 2020 | 27.50M |
| March 31, 2020 | 27.05M |
| December 31, 2019 | 23.56M |
| September 30, 2019 | 22.20M |
| June 30, 2019 | 22.60M |
| Date | Value |
|---|---|
| March 31, 2019 | 20.49M |
| December 31, 2018 | 19.04M |
| September 30, 2018 | 16.98M |
| June 30, 2018 | 14.76M |
| March 31, 2018 | 13.26M |
| December 31, 2017 | 13.74M |
| September 30, 2017 | 13.36M |
| June 30, 2017 | 12.00M |
| March 31, 2017 | 10.65M |
| December 31, 2016 | 9.000M |
| September 30, 2016 | 9.572M |
| June 30, 2016 | 9.975M |
| March 31, 2016 | 8.705M |
| December 31, 2015 | 6.967M |
| September 30, 2015 | 3.890M |
| June 30, 2015 | 2.171M |
| March 31, 2015 | 22.31M |
| December 31, 2014 | 22.22M |
| September 30, 2014 | 22.08M |
| June 30, 2014 | 21.30M |
| March 31, 2014 | 0.1228M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
23.56M
Minimum
Dec 2019
91.16M
Maximum
Sep 2024
49.16M
Average
46.37M
Median
Research and Development Expense (TTM) Benchmarks
| Amgen Inc | 5.774B |
| Eli Lilly and Co | 10.53B |
| Pfizer Inc | 10.60B |
| Structure Therapeutics Inc | 80.29M |
| Altimmune Inc | 77.94M |